The current paradigm on Parkinson's disease (PD) pathogenesis and course suggests the involvement of multiple genes and the interaction between them. Recently, it was reported that a variation (rs2435207) in the MAPT gene region influenced the age of motor symptoms onset (AO) in 44 PD patients from 19 families, carriers of leucine-rich repeat kinase 2 (LRRK2) mutations, all of European and North American origin. To examine whether genetic factors within the MAPT locus exert a similar effect on AO in a different population of LRRK2-associated PD patients, 99 unrelated Ashkenazi patients with the LRRK2 p.G2019S mutation were analyzed. Three SNPs in the MAPT region were studied, rs393152, rs2435207, and rs11079727; the latter is located in the first intron of MAPT. Among carriers of the single LRRK2 p.G2019S mutation that did not carry a founder Ashkenazi GBA mutation too (n = 84), the AO in minor rs11079727 A allele carriers (C/A genotype) was significantly older (62.5 ± 10.6 years) compared to the AO (55.7 ± 11.6) among carriers of the C/C genotype (p = 0.025). Our results further support a possible interaction between genetic factors in the MAPT region and the LRRK2 gene, which influence the clinical course of PD patients.
Parkinson’s disease MAPT Tau LRRK2
This is a preview of subscription content, log in to check access.
This work was supported by Tel Aviv Sourasky Medical Center Grant of Excellence, by Kahn Foundation, by the Chief Scientist of the Israeli Ministry of Health (grant No. 3–4893), by the Legacy Heritage Biomedical Science Partnership Program of the Israel Science Foundation (grant No.1922/08), by the National Parkinson Foundation, USA, and by Wolfson and Michael J. Fox Foundations. This work was performed in partial fulfillment of the requirements for a Ph.D. degree of Ziv Gan-Or, Sackler Faculty of medicine, Tel Aviv University, Israel.
Conflict of Interests
All authors declare that they have no conflict of interest related to this work.
Biernacka JM, Armasu SM, Cunningham JM, Eric Ahlskog J, Chung SJ, Maraganore DM (2011) Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility? Parkinsonism Relat Disord. doi:10.1016/j.parkreldis.2011.07.001
Cookson M (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11(12):791–797PubMedCrossRefGoogle Scholar
Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70:2277–2283PubMedCrossRefGoogle Scholar
Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N et al (2010) LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics 11:121–125PubMedCrossRefGoogle Scholar
Gan-Or Z, Bar-Shira A, Gurevich T, Giladi N, Orr-Urtreger A (2011) Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age at onset in GBA-associated Parkinson’s disease. Neurogenetics. doi:10.1007/s10048-011-0293-6
Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ et al (2009) Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord 15:539–541PubMedCrossRefGoogle Scholar
Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case–control study. Lancet Neurol 7(7):583–590PubMedCrossRefGoogle Scholar
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRefGoogle Scholar
Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM et al (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40:503–517PubMedCrossRefGoogle Scholar
Miklossy J, Qing H, Guo JP, Yu S, Wszolek ZK, Calne D et al (2007) Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol 114:243–254PubMedCrossRefGoogle Scholar
Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T et al (2007) The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 69:1595–1602PubMedCrossRefGoogle Scholar
Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ et al (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67:1506–1508PubMedCrossRefGoogle Scholar
Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41:1308–1312PubMedCrossRefGoogle Scholar
Skipper L, Wilkes K, Toft M, Baker M, Lincoln S, Hulihan M et al (2004) Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet 75:669–677PubMedCrossRefGoogle Scholar